CompanyKALANasdaqArlington, MA

KALA BIO, Inc.

KALA BIO develops mesenchymal stem cell secretome therapies for rare eye diseases.

SEC EDGAR ClinicalTrials.gov

424B3Sep 25Latest SEC filing

Sep 10Latest story

September 2026

Kala Bio confirms terms of exclusive Virotek eye genetic testing distribution deal

Sep 10PartnershipKALA BIO, Inc.

July 2026

KALA BIO files for up to $250 million at-the-market stock offering

Jul 22FinancingKALA BIO, Inc.